.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The WISDOM randomized trial tested a clinically important question: can inhaled corticosteroids be withdrawn from severe COPD patients who are already receiving dual long-acting bronchodilation? Patients underwent a stepwise reduction in inhaled glucocorticoid dose while continuing tiotropium and salmeterol. The primary outcome was the time to first moderate or severe exacerbation over a 12-month period. Gradual withdrawal did not meet criteria for a clinically important increase in exacerbation risk compared with continued triple therapy, although a modest additional decline in FEV1 occurred during withdrawal. The practical lesson is not that inhaled corticosteroids should routinely be stopped. Rather, the study supports individualized reassessment of the need for ICS after optimizing bronchodilation, especially when the indication for continued ICS is uncertain. In the NAPCON context, this fits directly with the COPD session's focus on moving from guideline strategy to real-world treatment decisions and on making the ICS choice more phenotype- and risk-based. Clinicians should still consider exacerbation history, eosinophil profile, asthma features, prior response and pneumonia risk before stepping down.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The WISDOM randomized trial tested a clinically important question: can inhaled corticosteroids be withdrawn from severe COPD patients who are already receiving dual long-acting bronchodilation? Patients underwent a stepwise reduction in inhaled glucocorticoid dose while continuing tiotropium and salmeterol. The primary outcome was the time to first moderate or severe exacerbation over a 12-month period. Gradual withdrawal did not meet criteria for a clinically important increase in exacerbation risk compared with continued triple therapy, although a modest additional decline in FEV1 occurred during withdrawal. The practical lesson is not that inhaled corticosteroids should routinely be stopped. Rather, the study supports individualized reassessment of the need for ICS after optimizing bronchodilation, especially when the indication for continued ICS is uncertain. In the NAPCON context, this fits directly with the COPD session's focus on moving from guideline strategy to real-world treatment decisions and on making the ICS choice more phenotype- and risk-based. Clinicians should still consider exacerbation history, eosinophil profile, asthma features, prior response and pneumonia risk before stepping down.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
